17:I[462708,["/_next/static/chunks/3yo3kiro3bmlp.js","/_next/static/chunks/3vr2wvd8f2efb.js","/_next/static/chunks/2vtmb68_vu-9t.js","/_next/static/chunks/2s8mt6_8wrpfo.js","/_next/static/chunks/3vkulz2i3l61y.js","/_next/static/chunks/1cqw2i1silz0i.js","/_next/static/chunks/14dbm3lm_t629.js","/_next/static/chunks/335_v2mb569ld.js","/_next/static/chunks/3ykn5ops9bft5.js","/_next/static/chunks/3cmavum774kjt.js","/_next/static/chunks/3th-0-a2xf9qs.js","/_next/static/chunks/0p0xpwde6kzmv.js","/_next/static/chunks/401-sxxnzbtf_.js","/_next/static/chunks/0wywtv698a1v0.js","/_next/static/chunks/2botzqwpnrzyj.js"],"ArticleReader"] 18:Ta1d4,## One-minute summary A **hypertensive emergency** is severe blood-pressure elevation accompanied by **new or worsening acute target-organ damage**. The number on the sphygmomanometer alone does not define the emergency. Acute encephalopathy, intracerebral hemorrhage, acute aortic syndrome, acute coronary ischemia, cardiogenic pulmonary edema, acute kidney injury, retinal injury, thrombotic microangiopathy, catecholamine crisis, and severe hypertensive disorders of pregnancy are examples of syndromes in which severe hypertension may require immediate treatment.[1–3] The 2025 AHA/ACC high-blood-pressure guideline defines severe hypertension as generally **SBP >180 mm Hg and/or DBP >120 mm Hg**. If there is acute target-organ damage, the patient has a hypertensive emergency and should be managed in a monitored setting with rapid diagnostic clarification and, in most cases, short-acting titratable intravenous antihypertensive therapy.[1] For hypertensive emergencies **without a disease-specific compelling target**, a practical default is: - lower systolic pressure by **no more than about 25% during the first hour**; - if stable, reduce toward approximately **<160/100–110 mm Hg over the next 2–6 hours**; - then continue cautious reduction toward usual long-term targets over the following **24–48 hours**.[1] This generic rule has major exceptions. **Aortic dissection, acute ischemic stroke, intracerebral hemorrhage, and pregnancy-related severe hypertension require syndrome-specific targets and timelines.**[1,4–6] The most important modern distinction is between: 1. **hypertensive emergency:** severe BP elevation **plus acute organ injury** → urgent monitored treatment; 2. **severe asymptomatic hypertension:** severe BP elevation **without acute organ injury** → do **not** reflexively use IV medication or rapidly normalize BP; address measurement error, pain, anxiety, missed medications, secondary drivers, and arrange appropriate oral treatment/follow-up.[1,2] ★ **HIGH YIELD:** Treat the **organ injury**, not merely the blood-pressure number. --- ## 1. Definitions and terminology ### Severe hypertension The 2025 AHA/ACC guideline uses **BP >180/120 mm Hg** as a threshold for severe hypertension in nonpregnant adults.[1] This threshold is a trigger for careful reassessment and evaluation, not automatic proof of an emergency. ### Hypertensive emergency **Severe hypertension + acute hypertension-mediated target-organ damage.** Typical organ systems include: - **Brain:** hypertensive encephalopathy, posterior reversible encephalopathy syndrome (PRES), intracerebral hemorrhage, selected ischemic-stroke scenarios - **Aorta/large vessels:** acute aortic dissection or other acute aortic syndrome - **Heart/lungs:** acute coronary syndrome, acute left-ventricular failure, hypertensive cardiogenic pulmonary edema - **Kidneys:** acute kidney injury from malignant hypertension or severe hypertensive nephropathy - **Retina:** acute grade III/IV hypertensive retinopathy with hemorrhages, exudates, or papilledema in the proper clinical context - **Microvasculature:** thrombotic microangiopathy / microangiopathic hemolysis related to severe hypertension - **Pregnancy:** acute severe hypertension in preeclampsia/eclampsia or related pregnancy syndromes - **Catecholamine excess:** pheochromocytoma crisis, sympathomimetic toxicity, monoamine-oxidase inhibitor interactions, or selected withdrawal syndromes[1–3] ### Severe asymptomatic hypertension Severe BP elevation **without new acute target-organ damage**. Headache, anxiety, pain, or epistaxis alone do not establish hypertensive emergency. The 2024 AHA scientific statement and 2025 AHA/ACC guideline caution that aggressive acute treatment of asymptomatic inpatient BP elevation can cause harm, including hypotension and kidney injury.[1,2] ⚠ **COMMON TRAP:** The obsolete concept of “hypertensive urgency” often encouraged rapid treatment of a number rather than a syndrome. Contemporary guidance favors distinguishing acute target-organ damage from severe BP elevation without acute injury.[1,2] --- ## 2. Pathophysiology Hypertensive emergencies usually reflect a failure of normal vascular autoregulation. A rapid or extreme rise in pressure increases wall stress and endothelial injury. Consequences may include: 1. endothelial dysfunction and increased vascular permeability; 2. activation of the renin–angiotensin–aldosterone and sympathetic systems; 3. arteriolar fibrinoid injury and narrowing; 4. tissue ischemia; 5. platelet activation and microangiopathic hemolysis; 6. further vasoconstriction and pressure escalation. The relationship between absolute BP and organ injury is modified by the patient’s usual pressure and the **rate of change**. A patient with chronically severe hypertension may tolerate a pressure that causes encephalopathy in someone with previously normal BP. Conversely, pregnancy, catecholamine excess, acute glomerular disease, or autonomic crises can cause severe organ injury at pressures below traditional emergency thresholds. ### Autoregulation explains why overshoot is dangerous The brain, kidneys, and coronary circulation adapt to chronic hypertension by shifting their autoregulatory range upward. Abrupt normalization can push perfusion below the lower autoregulatory limit, producing cerebral, myocardial, or renal ischemia. This is why most hypertensive emergencies require **controlled reduction rather than immediate normalization**.[1–3] --- ## 3. Causes and precipitants Common precipitating settings include: - previously undiagnosed or poorly controlled chronic hypertension; - abrupt discontinuation of clonidine or other sympatholytic therapy; - nonadherence to antihypertensives; - acute kidney disease, glomerulonephritis, renal artery disease; - pregnancy-related hypertensive disorders; - endocrine or catecholamine excess, including pheochromocytoma; - cocaine, amphetamine, synthetic stimulant, or other sympathomimetic exposure; - pain, agitation, autonomic dysreflexia, severe withdrawal; - drug interactions, including monoamine-oxidase inhibitor interactions; - acute aortic syndrome; - acute coronary or heart-failure syndromes; - central neurologic catastrophes such as stroke or intracranial hemorrhage. Always ask whether the severe BP is **the cause of organ injury, a physiologic response to organ injury, or both**. For example, acute ischemic stroke often causes reactive BP elevation; indiscriminate reduction can worsen cerebral perfusion.[5] --- ## 4. First 5 minutes: confirm the syndrome ### Immediate priorities | Component | Assessment | Interpretation | Immediate action | Anticipate deterioration | |---|---|---|---|---| | Airway | Voice, consciousness, secretions, seizure, vomiting | Reduced consciousness may threaten airway | Position, suction, airway support; early expert help if deteriorating | Encephalopathy/ICH may worsen rapidly | | Breathing | RR, SpO₂, work of breathing, crackles, frothy sputum | Pulmonary edema may be the target-organ injury | Oxygen only if hypoxemic; NIV when appropriate; prepare intubation if failing | Sudden fatigue, worsening edema | | Circulation | Repeat BP correctly, HR/rhythm, perfusion, pulses in all limbs | Pulse deficit or abrupt pain suggests aortic syndrome | Monitor, IV access, ECG; immediate anti-impulse therapy if dissection suspected | Rupture, shock, ischemia | | Disability | GCS/mental status, focal deficits, seizure, headache, vision | Encephalopathy, ICH, AIS, PRES | Glucose, urgent neuroimaging as indicated; follow stroke-specific BP targets | Herniation, seizure | | Exposure | Pregnancy status, edema, rash, stimulant clues, medication patches | Secondary cause or pregnancy syndrome may be apparent | Pregnancy testing when relevant; remove/stop causative drug | Eclampsia, toxidrome | ### Confirm the blood pressure Before committing to a diagnosis, unless the patient is crashing: - use an appropriately sized cuff; - repeat the measurement after a brief interval; - measure both arms when acute aortic syndrome is plausible; - consider manual confirmation when the automated reading is implausible, rhythm is irregular, or cuff fit is poor; - identify severe pain, agitation, hypoxemia, urinary retention, withdrawal, or medication omission that can transiently elevate BP. A markedly abnormal BP remains clinically important even when a reversible contributor exists, but measurement error is common and can lead to iatrogenic hypotension. --- ## 5. Identify acute target-organ damage ### Neurologic Look for: - confusion, agitation, drowsiness; - seizures; - visual disturbance; - severe headache with neurologic change; - focal weakness, aphasia, neglect, ataxia; - papilledema or retinal hemorrhage/exudate; - nausea/vomiting with altered cognition. #### Hypertensive encephalopathy / PRES The key syndrome is **diffuse cerebral dysfunction from failed autoregulation**, often with headache, confusion, visual symptoms, seizure, and sometimes MRI findings compatible with vasogenic edema. Diagnosis requires exclusion of stroke, hemorrhage, metabolic causes, infection, intoxication, and seizure-related states. ### Cardiovascular Evaluate for: - chest pain or pressure; - acute dyspnea/orthopnea; - pulmonary crackles, hypoxemia, pink frothy sputum; - new ischemic ECG changes; - elevated cardiac biomarkers in the correct context; - pulse asymmetry, neurologic deficits, new aortic regurgitation, or tearing chest/back pain suggesting acute aortic syndrome. ### Renal and hematologic Check for: - rising creatinine; - oliguria; - hematuria/proteinuria; - thrombocytopenia; - schistocytes; - elevated LDH with low haptoglobin suggesting microangiopathic hemolysis. Severe hypertension can both cause and result from kidney injury. Thrombotic microangiopathy from malignant hypertension may mimic thrombotic thrombocytopenic purpura; the broader clinical context and ADAMTS13 testing may be important when TTP remains possible. ### Ophthalmic Fundoscopy can identify: - flame hemorrhages; - cotton-wool spots; - hard exudates; - papilledema. Retinal findings support acute microvascular injury but absence of papilledema does not exclude a hypertensive emergency. --- ## 6. Diagnostic workup Testing should be driven by the suspected organ injury rather than by BP alone. ### Common initial studies - 12-lead ECG - serum creatinine, electrolytes, glucose - CBC with platelets - urinalysis ± urine protein assessment - high-sensitivity troponin when ACS or myocardial injury is suspected - pregnancy test when relevant - chest radiograph for pulmonary edema or thoracic symptoms - point-of-care ultrasound where expertise exists ### Add when indicated - noncontrast CT head for acute neurologic symptoms - CTA head/neck for suspected stroke or vascular pathology - CTA chest/abdomen/pelvis for suspected acute aortic syndrome - echocardiography for acute heart failure, structural disease, or aortic regurgitation - LDH, bilirubin, haptoglobin, reticulocytes, peripheral smear for suspected microangiopathic hemolysis - toxicology testing when it would change management - plasma/urine metanephrine testing **after stabilization** when pheochromocytoma remains plausible; do not delay crisis treatment for confirmatory testing. ★ **NEXT BEST STEP:** In suspected aortic dissection or stroke, imaging and organ-specific therapy should proceed in parallel with controlled BP treatment; do not spend an hour completing a routine hypertension workup first. --- ## 7. General treatment principles ### STANDARD OF CARE 1. **Treat in a monitored environment.** Hypertensive emergency generally warrants ICU or equivalent high-acuity monitoring.[1] 2. **Use titratable short-acting IV medication** for most true emergencies.[1] 3. **Choose the drug according to the organ syndrome.** 4. **Avoid excessive early reduction** unless a compelling condition requires it.[1] 5. **Reassess perfusion and organ function continuously.** 6. **Transition to oral therapy only after the acute syndrome is controlled and the trajectory is stable.** ### Generic BP goal when there is no compelling condition The 2025 AHA/ACC guideline recommends avoiding an initial SBP reduction greater than about **25% in the first hour**, followed by reduction to **<160/100–110 mm Hg over the next 2–6 hours**, then cautious normalization over the next 24–48 hours.[1] This is not the target for aortic dissection, acute stroke, intracerebral hemorrhage, or pregnancy-related severe hypertension. --- ## 8. Intravenous antihypertensive medications Doses below are adult guideline ranges and assume a monitored setting. Adjust for age, organ function, contraindications, and local protocols.[1,7] | Drug | Typical adult dosing | Useful clinical contexts | Major cautions / limitations | |---|---|---|---| | **Nicardipine** | Start **5 mg/h IV**; increase by **2.5 mg/h every 5 min** to max **15 mg/h** | Encephalopathy, many neurologic emergencies, general titratable BP control | Avoid/individualize in advanced aortic stenosis; reflex tachycardia possible | | **Clevidipine** | Start **1–2 mg/h IV**, rapidly titrate by doubling every ~90 s until near goal, then smaller increases; 2025 AHA/ACC table lists max **21 mg/h** | Very rapid titration; neurologic/cardiac settings | Lipid emulsion; avoid in relevant egg/soy-product allergy and major lipid-metabolism disorders; follow product/local maximums | | **Labetalol** | Intermittent IV bolus or infusion; common emergency regimens use **10–20 mg IV initially**, then repeated/titrated doses or infusion per protocol | Many emergencies; pregnancy; aortic syndrome when appropriate | Bradycardia, heart block, asthma/bronchospasm, decompensated systolic HF | | **Esmolol** | **0.5–1 mg/kg IV loading**, then **50–300 mcg/kg/min** infusion | Acute aortic syndrome; situations requiring rapidly reversible beta-blockade | Bradycardia, AV block, acute decompensated HF, bronchospasm risk | | **Nitroglycerin** | Start around **5 mcg/min IV**, titrate rapidly to clinical/BP response using local protocol | Acute pulmonary edema, ACS with hypertension | Headache, tachyphylaxis; profound hypotension with PDE-5 inhibitors; weak arterial effect at low doses | | **Sodium nitroprusside** | Start **0.3–0.5 mcg/kg/min IV**, titrate; use shortest duration possible | Selected refractory emergencies, after beta-blockade in some aortic cases | Cyanide/thiocyanate toxicity, overshoot hypotension; caution renal/hepatic dysfunction; invasive BP monitoring often appropriate | | **Hydralazine** | Common urgent regimen **5–10 mg IV**, repeat per protocol | Pregnancy-related severe hypertension when used in obstetric protocol | Response can be unpredictable and prolonged; not preferred for most nonpregnant emergencies | | **Phentolamine** | Common crisis dosing **2–5 mg IV**, repeated as needed under close monitoring | Pheochromocytoma/catecholamine excess | Tachycardia, hypotension; specialist guidance advised | #### Why nicardipine and clevidipine are often attractive They provide smooth, easily titratable arterial vasodilation. The 2025 guideline notes limited trials suggesting nicardipine may reach short-term BP targets more reliably than labetalol and clevidipine may lower pressure faster than nicardipine, but there is **no high-quality evidence that one IV agent improves mortality across all hypertensive emergencies**.[1] #### Why nitroprusside is no longer a universal default It is potent and rapidly titratable but carries risks of overshoot hypotension and cyanide/thiocyanate toxicity. More organ-specific agents are usually preferred when available.[1,7] --- ## 9. Syndrome-specific treatment ### 9.1 Acute aortic syndrome / aortic dissection This is one of the most time-critical BP emergencies. #### Goal The 2025 AHA/ACC guideline recommends **SBP ≤120 mm Hg within about 20 minutes**, provided organ perfusion is maintained.[1] #### Sequence matters 1. Start **beta-blockade first** to reduce heart rate and aortic wall impulse (commonly esmolol or labetalol). 2. If SBP remains above goal, add a titratable vasodilator such as nicardipine or nitroprusside. 3. Provide aggressive analgesia and immediate cardiothoracic/vascular surgical consultation. ⚠ **COMMON TRAP:** Starting a pure vasodilator before adequate beta-blockade may increase reflex tachycardia and shear stress. #### Practical targets - SBP: generally **≤120 mm Hg**, individualized to maintain perfusion[1] - HR: often targeted near **60 beats/min** in anti-impulse protocols[7] --- ### 9.2 Acute ischemic stroke Do **not** apply the generic 25%-reduction rule automatically. The 2026 AHA/ASA acute ischemic stroke guideline recommends:[5] - **Before IV thrombolysis:** lower BP to **<185/110 mm Hg**. - **After IV thrombolysis:** maintain **<180/105 mm Hg for at least 24 hours**. - **Before EVT when IV thrombolysis was not given:** maintaining **≤185/110 mm Hg** is reasonable. - **During and for 24 hours after EVT:** maintaining **≤180/105 mm Hg** is reasonable. - After successful thrombectomy, **intensive SBP lowering to <140 mm Hg is harmful and is not recommended** in the populations addressed by the guideline.[5] For patients not undergoing reperfusion, permissive hypertension is often appropriate unless BP is extremely high or another compelling emergency such as aortic dissection, acute coronary syndrome, or pulmonary edema requires treatment. Follow the current stroke protocol. --- ### 9.3 Spontaneous intracerebral hemorrhage For patients with **mild-to-moderate ICH** presenting with SBP **150–220 mm Hg**, the 2022 AHA/ASA guideline states that acute lowering to a target near **140 mm Hg**, maintaining approximately **130–150 mm Hg**, is safe and may be reasonable. Acute lowering to **<130 mm Hg** is potentially harmful.[4] Priorities: - smooth sustained control rather than oscillating BP; - rapid neuroimaging; - reversal of anticoagulation when indicated; - neurosurgical/neurocritical-care consultation; - management of intracranial pressure and other ICH priorities. --- ### 9.4 Hypertensive encephalopathy / PRES When diffuse neurologic dysfunction is attributed to severe hypertension after excluding hemorrhage, ischemic stroke, metabolic disease, infection, and toxic causes: - use a titratable IV agent such as nicardipine or labetalol; - generally reduce MAP/SBP cautiously, often using the default **no more than ~25% in the first hour** principle; - avoid rapid normalization; - treat seizures when present; - obtain MRI when PRES is suspected and the patient is stable enough. Clinical improvement in mental status with controlled BP reduction supports the diagnosis but is not a substitute for excluding other emergencies. --- ### 9.5 Acute cardiogenic pulmonary edema with severe hypertension The pathophysiology is often abrupt afterload excess with pulmonary vascular congestion; some patients are not markedly volume overloaded. #### Priorities - noninvasive positive-pressure ventilation when appropriate; - IV **nitroglycerin** when severe hypertension/afterload excess is prominent; - a titratable arterial vasodilator such as clevidipine in selected patients; - loop diuretic when true congestion/volume overload is present; - treat ACS, arrhythmia, renal failure, or valve disease when causative.[1] **Beta-blockers are not used to acutely lower BP in active pulmonary edema with decompensated heart failure.**[1] ⚠ **COMMON TRAP:** Giving repeated fluid boluses because the patient is tachycardic despite clear pulmonary edema. --- ### 9.6 Acute coronary syndrome with severe hypertension Goals are to reduce myocardial oxygen demand without compromising coronary perfusion. Options may include: - IV nitroglycerin for persistent ischemia/hypertension when not contraindicated; - beta-blockade in appropriately selected patients without acute heart failure, shock, bradycardia, or conduction disease; - nicardipine or other titratable agents when needed.[1] Avoid precipitous reductions in diastolic pressure, especially in patients with severe coronary disease who depend on diastolic coronary perfusion. --- ### 9.7 Acute kidney injury / malignant hypertension The patient may have: - rising creatinine; - hematuria/proteinuria; - retinal injury; - microangiopathic hemolytic anemia; - thrombocytopenia. Use controlled IV BP reduction and carefully monitor renal function, urine output, potassium, acid-base status, and hemolysis markers. Nicardipine or other titratable agents are commonly used; the choice should reflect the clinical context and local critical-care practice. A transient creatinine rise can occur during BP reduction because autoregulation is being reset. The aim is not to preserve the presenting pressure but to avoid excessive hypotension while preventing ongoing vascular injury. --- ### 9.8 Pheochromocytoma or catecholamine crisis Features can include episodic or sustained severe hypertension, tachycardia, diaphoresis, headache, hyperglycemia, lactic acidosis, cardiomyopathy, pulmonary edema, or shock. #### Principle **Alpha blockade/vasodilation must precede unopposed beta blockade** when catecholamine excess is suspected. IV phentolamine, nicardipine, or other expert-directed vasodilator therapy may be used.[1,7] ⚠ **RED FLAG:** Pure beta-blockade before adequate alpha control in pheochromocytoma can worsen vasoconstriction and hypertension. --- ### 9.9 Severe hypertension in pregnancy / postpartum Severe-range pregnancy hypertension is generally **SBP ≥160 mm Hg and/or DBP ≥110 mm Hg**. ACOG recommends urgent treatment, ideally within **30–60 minutes** of confirmed persistent severe hypertension, to reduce maternal stroke risk.[6] First-line urgent agents include: - **IV labetalol**; - **IV hydralazine**; - **immediate-release oral nifedipine**, especially when IV access is not yet available.[6] The 2025 AHA/ACC guideline reproduces commonly used urgent pregnancy regimens, including labetalol **10–20 mg IV initially**, hydralazine **5 mg IV/IM initially**, and nifedipine **10–20 mg orally**, with protocolized repeat dosing.[1] If preeclampsia with severe features/eclampsia is present, magnesium sulfate and obstetric decision-making regarding delivery are separate critical priorities. Do not manage pregnancy-related severe hypertension as a routine nonpregnant hypertensive emergency. --- ## 10. Severe asymptomatic hypertension: what not to do The 2024 AHA scientific statement and 2025 AHA/ACC guideline emphasize that inpatient or ED patients with severe BP elevation **without acute target-organ injury** should not routinely receive IV antihypertensive therapy solely to normalize a number.[1,2] ### Better approach 1. Recheck BP with correct technique. 2. Treat pain, anxiety, hypoxemia, urinary retention, withdrawal, or other reversible stressors. 3. Determine whether chronic antihypertensives were missed or held. 4. Assess for symptoms/signs of organ injury. 5. Restart or adjust an oral regimen when appropriate. 6. Arrange timely outpatient follow-up and evaluation for chronic hypertension/secondary causes. Observational studies cited by the AHA have associated unnecessary acute inpatient treatment with hypotension, AKI, and longer hospitalization.[2] ★ **HIGH YIELD:** Severe BP **without** acute organ injury is not a reason to “chase the number” with PRN IV medication. --- ## 11. Monitoring and reassessment ### Continuous or frequent monitoring - BP every few minutes during active titration - continuous ECG - pulse oximetry when respiratory compromise is possible - neurologic checks for brain syndromes - urine output in severe disease - serial creatinine/electrolytes - serial troponin/ECG when ACS is suspected - serial hemolysis studies when microangiopathy is present An arterial catheter is reasonable when very rapid titration is required, when noninvasive measurements are unreliable, or when the margin between adequate treatment and hypoperfusion is narrow. ### Reassessment questions after each dose/titration - Has the target pressure been reached too quickly? - Is mental status improving or worsening? - Is chest pain resolving? - Is oxygenation/work of breathing improving? - Is urine output preserved? - Are new neurologic deficits appearing? - Are limb perfusion or pulses changing? - Is the patient becoming dizzy, oliguric, bradycardic, or hypotensive? --- ## 12. Anticipation of deterioration | Scenario | Warning signs | What to prepare for | |---|---|---| | Aortic dissection | new hypotension, pulse loss, neurologic deficit, pericardial effusion, severe aortic regurgitation | immediate surgery/transfer, blood products, airway/critical care | | ICH/PRES | falling GCS, recurrent seizure, anisocoria | airway control, repeat CT, neurocritical care, ICP management | | Pulmonary edema | rising work of breathing, refractory hypoxemia, fatigue | NIV escalation, intubation, vasodilator intensification | | ACS | ventricular arrhythmia, shock, ongoing ischemia | cath-lab pathway, defibrillation capability, mechanical support evaluation | | Malignant hypertension/TMA | worsening AKI, hemolysis, thrombocytopenia | nephrology/hematology input, dialysis preparation, exclude TTP | | Pregnancy | seizure, pulmonary edema, fetal compromise, HELLP features | magnesium, obstetric emergency response, delivery planning | | Catecholamine crisis | hyperthermia, cardiomyopathy, arrhythmia, shock | ICU, alpha-directed therapy, mechanical support if needed | --- ## 13. Transition to oral therapy Once the emergency is controlled: - identify the chronic BP regimen and adherence barriers; - investigate secondary hypertension when clinically indicated; - transition from IV to oral agents with sufficient overlap to prevent rebound; - simplify the regimen when possible; - address substance use or medication triggers; - arrange kidney, cardiology, neurology, obstetric, vascular, or endocrine follow-up as appropriate; - establish a home BP plan with validated cuff and clear thresholds for seeking care. Avoid discharging a patient after a true hypertensive emergency without a plan for the organ injury itself; BP control is only one component of definitive care. --- ## 14. Secondary hypertension clues after stabilization Consider targeted workup for: - primary aldosteronism; - renal parenchymal disease; - renal artery stenosis/fibromuscular dysplasia; - pheochromocytoma/paraganglioma; - Cushing syndrome; - thyroid disease; - obstructive sleep apnea; - coarctation; - drug/substance causes. The 2025 AHA/ACC guideline expanded emphasis on detection of secondary causes, including broader screening for primary aldosteronism in resistant hypertension.[1] --- ## 15. Common pitfalls | Pitfall | Why it is dangerous | Better approach | |---|---|---| | Defining emergency by BP alone | Leads to unnecessary IV therapy | Require acute target-organ injury | | Rapidly normalizing chronic severe hypertension | Cerebral, coronary, renal hypoperfusion | Controlled syndrome-specific reduction | | Using generic 25% rule in aortic dissection | Too slow for a time-critical aortic catastrophe | Anti-impulse therapy; SBP ≤120 rapidly if tolerated | | Lowering BP aggressively in ischemic stroke without indication | Can reduce penumbral perfusion | Follow 2026 stroke-specific thresholds | | Treating post-thrombectomy BP to <140 routinely | 2026 AHA/ASA guideline identifies harm | Use current EVT target protocol | | Pure beta-blockade in pheochromocytoma | Unopposed alpha vasoconstriction | Alpha blockade/vasodilation first | | Beta-blocker for active hypertensive pulmonary edema | May worsen decompensated HF | Vasodilator + ventilatory support; treat congestion/cause | | PRN IV hydralazine for asymptomatic inpatient BP | Unpredictable fall and no proven benefit | Correct drivers and use scheduled oral therapy when indicated | | Ignoring pregnancy-specific protocols | Maternal stroke/eclampsia risk | Treat persistent ≥160/110 promptly with obstetric pathway | | Forgetting medication withdrawal | Rebound hypertension persists | Identify clonidine/other withdrawal and treat appropriately | --- ## 16. Diagnostic and management algorithm ```text Severely elevated BP ↓ Repeat correctly + rapid ABCDE assessment ↓ Evidence of NEW/WORSENING acute target-organ damage? ├─ NO │ ↓ │ Severe asymptomatic hypertension │ - Treat pain/anxiety/hypoxemia/retention/withdrawal │ - Restart/intensify oral therapy when appropriate │ - Avoid reflex IV treatment │ - Arrange follow-up │ └─ YES ↓ Hypertensive emergency ↓ Identify dominant syndrome ├─ Aortic dissection → beta-block first → SBP ≤120 rapidly ├─ AIS → follow 2026 stroke BP thresholds ├─ ICH → smooth target ~140; maintain 130–150 if eligible ├─ Pulmonary edema → NIV + nitrate/vasodilator strategy ├─ ACS → anti-ischemic + titratable BP control ├─ Encephalopathy/PRES → controlled IV reduction ├─ Pregnancy → urgent obstetric protocol ├─ Catecholamine crisis → alpha-directed therapy └─ Other emergency → default ≤25% first-hour reduction ↓ Continuous reassessment of perfusion and organ function ↓ Definitive cause-specific treatment + transition to oral regimen ``` --- ## 17. Acute management checklist ### Recognition - [ ] Repeat BP with appropriate cuff/technique - [ ] Identify acute neurologic, cardiac, pulmonary, renal, retinal, aortic, pregnancy, or microangiopathic injury - [ ] Check medication adherence and recent drug/substance exposure ### Stabilization - [ ] Cardiac monitor and IV access - [ ] Oxygen only if hypoxemic; ventilatory support if needed - [ ] Obtain ECG and targeted labs - [ ] Obtain urgent imaging for neurologic or aortic syndrome - [ ] Choose **syndrome-specific** BP target - [ ] Use titratable IV agent for true emergency ### Reassessment - [ ] Confirm rate of BP decline is not excessive - [ ] Recheck neurologic status - [ ] Reassess chest pain and respiratory status - [ ] Track creatinine and urine output - [ ] Repeat organ-specific studies when clinically indicated ### Disposition - [ ] ICU/high-acuity care for true hypertensive emergency - [ ] Definitive specialty management of the injured organ - [ ] Transition to durable oral regimen - [ ] Evaluate secondary cause/adherence after stabilization --- ## 18. Guideline differences and jurisdiction notes ### United States: 2025 AHA/ACC The 2025 guideline provides a practical definition of hypertensive emergency, ICU disposition, the default staged reduction strategy, IV drug tables, and explicit disease-specific exceptions.[1] ### Europe: 2024 ESC The 2024 ESC guideline updates the broader framework for hypertension and reinforces individualized management of severe hypertension and acute organ injury. European practice also draws on the ESC Council position document on hypertensive emergencies, which emphasizes that the **type of organ injury determines the drug, target, and timeframe**.[3,7] ### Acute-care AHA statement The 2024 AHA scientific statement is especially important for avoiding **overtreatment of asymptomatic inpatient BP elevation**. It highlights the weak evidence base for treating a transient inpatient BP number in the absence of acute organ injury and the potential for harm.[2] ### Stroke The 2026 AHA/ASA ischemic stroke guideline supersedes older US acute-ischemic-stroke guidance and specifically warns against overly intensive BP lowering after thrombectomy.[5] --- ## 19. Standard of care vs emerging evidence ### STANDARD OF CARE - Diagnose hypertensive emergency by **acute target-organ injury**, not BP alone.[1–3] - ICU/high-acuity monitoring and IV titratable therapy for most true emergencies.[1] - Syndrome-specific targets for aorta, stroke, ICH, pregnancy, pulmonary edema, and ACS.[1,4–6] - Avoid rapid IV treatment of severe asymptomatic inpatient hypertension.[1,2] ### EMERGING EVIDENCE - Optimal BP targets after endovascular thrombectomy continue to evolve; recent randomized evidence has shifted practice away from intensive post-EVT lowering, reflected in the 2026 AHA/ASA guideline.[5] - Comparative effectiveness of nicardipine, clevidipine, and labetalol for hard clinical outcomes remains uncertain; existing trials mainly examine speed/precision of target achievement rather than mortality.[1] - Better phenotyping of malignant hypertension, hypertensive microangiopathy, and secondary causes may improve individualized therapy. ### EXPERIMENTAL / INVESTIGATIONAL - Novel biomarkers or automated closed-loop BP titration systems are not yet standard care. - Device-based chronic hypertension therapies such as renal denervation have no role in the initial stabilization of a hypertensive emergency. --- ## 20. Exam-focused review ### Foundation / USMLE Step 1 Know the physiology: - chronic hypertension shifts autoregulation to higher pressures; - abrupt normalization can cause ischemia; - hypertensive encephalopathy is a failure of cerebral autoregulation with vasogenic edema; - aortic dissection requires reduction of both BP and shear/impulse. ### USMLE Step 2 CK Priority questions usually test: - **organ injury present?** - **which syndrome determines the BP target?** - **IV or oral therapy?** - **what should happen before vasodilation in dissection?** ### Step 3 / Resident Be able to choose an agent and monitor complications: - nicardipine/clevidipine for smooth titration; - esmolol/labetalol for aortic impulse control; - nitroglycerin for hypertensive pulmonary edema/ACS; - pregnancy-specific labetalol/hydralazine/nifedipine pathway; - avoid unnecessary IV treatment in asymptomatic severe BP. ### MRCP / ABIM / Boards Expect nuanced questions involving: - malignant hypertension with AKI/TMA; - stroke-specific thresholds; - aortic dissection sequence; - catecholamine crisis and unopposed alpha effect; - acute pulmonary edema and why beta-blockade is inappropriate during active decompensation; - the distinction between chronic severe hypertension and acute end-organ injury. --- ## 21. Original board-style MCQs ### Question 1 A 64-year-old man has BP 228/132 mm Hg, acute tearing chest pain radiating to the back, and a new pulse deficit. He is alert and oxygenating well. Which initial pharmacologic strategy is best? A. IV nitroprusside before any rate control B. IV esmolol followed by titratable vasodilator if needed C. Oral amlodipine and observation D. IV hydralazine bolus only E. Sublingual nifedipine **Answer: B.** Suspected acute aortic syndrome requires rapid anti-impulse therapy. Beta-blockade should precede a pure vasodilator to prevent reflex tachycardia and increased shear. The target SBP is generally ≤120 mm Hg rapidly if perfusion is maintained.[1] --- ### Question 2 A hospitalized patient with pneumonia has repeated BP readings around 192/106 mm Hg but no chest pain, neurologic deficit, pulmonary edema, AKI, retinal findings, or other acute target-organ damage. Which approach best reflects current guidance? A. PRN IV hydralazine whenever SBP exceeds 180 B. IV nicardipine infusion to normalize BP within 2 hours C. Reassess measurement and reversible stressors, then use scheduled oral therapy if indicated D. Nitroprusside infusion E. Emergent dialysis **Answer: C.** Severe asymptomatic inpatient BP elevation should not routinely be treated with IV medication solely to lower the number. Treat reversible contributors and manage chronic hypertension deliberately.[1,2] --- ### Question 3 A patient with acute ischemic stroke is otherwise eligible for IV thrombolysis. BP is 198/118 mm Hg. What is the relevant pre-thrombolysis BP goal? A. <220/120 mm Hg B. <200/110 mm Hg C. <185/110 mm Hg D. <160/90 mm Hg E. <140/80 mm Hg **Answer: C.** The 2026 AHA/ASA guideline recommends reducing BP to <185/110 mm Hg before IV thrombolysis.[5] --- ### Question 4 A 58-year-old woman with mild-to-moderate spontaneous ICH presents with SBP 188 mm Hg. Which acute target is most consistent with AHA/ASA guidance? A. SBP <100 mm Hg immediately B. SBP <120 mm Hg immediately C. Target ~140 mm Hg and maintain approximately 130–150 mm Hg D. No BP treatment until 24 hours E. Target <130 mm Hg **Answer: C.** In eligible mild-to-moderate ICH with presenting SBP 150–220 mm Hg, smooth reduction toward 140 with maintenance 130–150 is safe and may be reasonable; <130 may be harmful.[4] --- ### Question 5 A patient with severe hypertension, diaphoresis, tachycardia, and known pheochromocytoma develops a crisis. Which principle is essential? A. Pure beta-blockade should precede all other therapy B. Alpha-directed vasodilation should precede unopposed beta-blockade C. BP should never be lowered acutely D. Oral thiazide is first-line emergency treatment E. Nitroglycerin is contraindicated in all catecholamine crises **Answer: B.** Unopposed beta-blockade can worsen alpha-mediated vasoconstriction. Alpha blockade/vasodilation should be established first.[1,7] --- ## 22. Key takeaways 1. **Hypertensive emergency = severe BP + acute target-organ damage.** 2. **A number alone is not an emergency.** 3. For most emergencies without a compelling condition, reduce BP cautiously: no more than ~25% in the first hour, then toward <160/100–110 over 2–6 hours.[1] 4. **Aortic dissection is different:** beta-block first; SBP ≤120 rapidly if tolerated.[1] 5. **Stroke is different:** follow 2026 AHA/ASA reperfusion-specific targets.[5] 6. **ICH is different:** smooth reduction toward ~140 with avoidance of <130 in eligible patients.[4] 7. **Pregnancy is different:** persistent severe-range BP requires urgent obstetric antihypertensive therapy.[6] 8. Do not reflexively treat severe asymptomatic inpatient BP with IV medication.[1,2] 9. Drug choice is determined by the injured organ and comorbidities. 10. Reassessment is continuous; overshoot hypotension can be as dangerous as undertreatment. --- ## References 1. Jones DW, Ferdinand KC, Taler SJ, et al. **2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.** *Circulation.* 2025. DOI: **10.1161/CIR.0000000000001356**. Parallel publication: *Hypertension.* 2025;82:e212-e316. DOI: **10.1161/HYP.0000000000000249**. JACC version DOI: **10.1016/j.jacc.2025.05.007**. 2. Bress AP, Anderson TS, Flack JM, et al. **The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association.** *Hypertension.* 2024;81:e94-e106. DOI: **10.1161/HYP.0000000000000238**. 3. McEvoy JW, McCarthy CP, Bruno RM, et al. **2024 ESC Guidelines for the management of elevated blood pressure and hypertension.** *Eur Heart J.* 2024;45:3912-4018. DOI: **10.1093/eurheartj/ehae178**. PMID: **39210715**. 4. Greenberg SM, Ziai WC, Cordonnier C, et al. **2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage.** *Stroke.* 2022;53:e282-e361. DOI: **10.1161/STR.0000000000000407**. 5. American Heart Association/American Stroke Association. **2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke.** *Stroke.* 2026;57:e316-e436. DOI: **10.1161/STR.0000000000000513**. 6. American College of Obstetricians and Gynecologists. **ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.** *Obstet Gynecol.* 2019;133:e174-e180. DOI: **10.1097/AOG.0000000000003075**. PMID: **30575639**. 7. van den Born BJH, Lip GYH, Brguljan-Hitij J, et al. **ESC Council on hypertension position document on the management of hypertensive emergencies.** *Eur Heart J Cardiovasc Pharmacother.* 2019;5:37-46. DOI: **10.1093/ehjcvp/pvy032**. PMID: **30165588**. Corrigendum DOI: **10.1093/ehjcvp/pvy040**. 8. American Heart Association. **2025 High Blood Pressure Guideline — Professional Heart Daily.** Updated August 14, 2025. Official guideline hub: https://professional.heart.org/en/science-news/2025-high-blood-pressure-guideline 9. European Society of Cardiology. **2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension.** Official guideline hub: https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/elevated-blood-pressure-and-hypertension/ --- **Evidence note:** The strongest contemporary sources for this article are the 2025 AHA/ACC adult blood-pressure guideline, the 2024 AHA acute-care scientific statement, the 2024 ESC hypertension guideline, the 2026 AHA/ASA ischemic-stroke guideline, and the 2022 AHA/ASA ICH guideline. Drug doses and targets must always be reconciled with local formularies, product labeling, organ-specific protocols, and the patient's physiology.19:Ta23a,## One-minute summary A **hypertensive emergency** is severe blood-pressure elevation accompanied by **new or worsening acute target-organ damage**. The number on the sphygmomanometer alone does not define the emergency. Acute encephalopathy, intracerebral hemorrhage, acute aortic syndrome, acute coronary ischemia, cardiogenic pulmonary edema, [acute kidney injury](/library/acute-kidney-injury), retinal injury, thrombotic microangiopathy, catecholamine crisis, and severe hypertensive disorders of pregnancy are examples of syndromes in which severe hypertension may require immediate treatment.[1–3] The 2025 AHA/ACC high-blood-pressure guideline defines severe hypertension as generally **SBP >180 mm Hg and/or DBP >120 mm Hg**. If there is acute target-organ damage, the patient has a hypertensive emergency and should be managed in a monitored setting with rapid diagnostic clarification and, in most cases, short-acting titratable intravenous antihypertensive therapy.[1] For hypertensive emergencies **without a disease-specific compelling target**, a practical default is: - lower systolic pressure by **no more than about 25% during the first hour**; - if stable, reduce toward approximately **<160/100–110 mm Hg over the next 2–6 hours**; - then continue cautious reduction toward usual long-term targets over the following **24–48 hours**.[1] This generic rule has major exceptions. **Aortic dissection, [acute ischemic stroke](/library/acute-ischemic-stroke), intracerebral hemorrhage, and pregnancy-related severe hypertension require syndrome-specific targets and timelines.**[1,4–6] The most important modern distinction is between: 1. **hypertensive emergency:** severe BP elevation **plus acute organ injury** → urgent monitored treatment; 2. **severe asymptomatic hypertension:** severe BP elevation **without acute organ injury** → do **not** reflexively use IV medication or rapidly normalize BP; address measurement error, pain, anxiety, missed medications, secondary drivers, and arrange appropriate oral treatment/follow-up.[1,2] ★ **HIGH YIELD:** Treat the **organ injury**, not merely the blood-pressure number. --- ## 1. Definitions and terminology ### Severe hypertension The 2025 AHA/ACC guideline uses **BP >180/120 mm Hg** as a threshold for severe hypertension in nonpregnant adults.[1] This threshold is a trigger for careful reassessment and evaluation, not automatic proof of an emergency. ### Hypertensive emergency **Severe hypertension + acute hypertension-mediated target-organ damage.** Typical organ systems include: - **Brain:** hypertensive encephalopathy, posterior reversible encephalopathy syndrome (PRES), intracerebral hemorrhage, selected ischemic-stroke scenarios - **Aorta/large vessels:** acute aortic dissection or other acute aortic syndrome - **Heart/lungs:** [acute coronary syndrome](/library/acute-coronary-syndrome), acute left-ventricular failure, hypertensive cardiogenic pulmonary edema - **Kidneys:** acute kidney injury from malignant hypertension or severe hypertensive nephropathy - **Retina:** acute grade III/IV hypertensive retinopathy with hemorrhages, exudates, or papilledema in the proper clinical context - **Microvasculature:** thrombotic microangiopathy / microangiopathic hemolysis related to severe hypertension - **Pregnancy:** acute severe hypertension in preeclampsia/eclampsia or related pregnancy syndromes - **Catecholamine excess:** pheochromocytoma crisis, sympathomimetic toxicity, monoamine-oxidase inhibitor interactions, or selected withdrawal syndromes[1–3] ### Severe asymptomatic hypertension Severe BP elevation **without new acute target-organ damage**. Headache, anxiety, pain, or epistaxis alone do not establish hypertensive emergency. The 2024 AHA scientific statement and 2025 AHA/ACC guideline caution that aggressive acute treatment of asymptomatic inpatient BP elevation can cause harm, including hypotension and kidney injury.[1,2] ⚠ **COMMON TRAP:** The obsolete concept of “hypertensive urgency” often encouraged rapid treatment of a number rather than a syndrome. Contemporary guidance favors distinguishing acute target-organ damage from severe BP elevation without acute injury.[1,2] --- ## 2. Pathophysiology Hypertensive emergencies usually reflect a failure of normal vascular autoregulation. A rapid or extreme rise in pressure increases wall stress and endothelial injury. Consequences may include: 1. endothelial dysfunction and increased vascular permeability; 2. activation of the renin–angiotensin–aldosterone and sympathetic systems; 3. arteriolar fibrinoid injury and narrowing; 4. tissue ischemia; 5. platelet activation and microangiopathic hemolysis; 6. further vasoconstriction and pressure escalation. The relationship between absolute BP and organ injury is modified by the patient’s usual pressure and the **rate of change**. A patient with chronically severe hypertension may tolerate a pressure that causes encephalopathy in someone with previously normal BP. Conversely, pregnancy, catecholamine excess, acute glomerular disease, or autonomic crises can cause severe organ injury at pressures below traditional emergency thresholds. ### Autoregulation explains why overshoot is dangerous The brain, kidneys, and coronary circulation adapt to chronic hypertension by shifting their autoregulatory range upward. Abrupt normalization can push perfusion below the lower autoregulatory limit, producing cerebral, myocardial, or renal ischemia. This is why most hypertensive emergencies require **controlled reduction rather than immediate normalization**.[1–3] --- ## 3. Causes and precipitants Common precipitating settings include: - previously undiagnosed or poorly controlled chronic hypertension; - abrupt discontinuation of clonidine or other sympatholytic therapy; - nonadherence to antihypertensives; - acute kidney disease, glomerulonephritis, renal artery disease; - pregnancy-related hypertensive disorders; - endocrine or catecholamine excess, including pheochromocytoma; - cocaine, amphetamine, synthetic stimulant, or other sympathomimetic exposure; - pain, agitation, autonomic dysreflexia, severe withdrawal; - drug interactions, including monoamine-oxidase inhibitor interactions; - acute aortic syndrome; - acute coronary or heart-failure syndromes; - central neurologic catastrophes such as stroke or intracranial hemorrhage. Always ask whether the severe BP is **the cause of organ injury, a physiologic response to organ injury, or both**. For example, acute ischemic stroke often causes reactive BP elevation; indiscriminate reduction can worsen cerebral perfusion.[5] --- ## 4. First 5 minutes: confirm the syndrome ### Immediate priorities | Component | Assessment | Interpretation | Immediate action | Anticipate deterioration | |---|---|---|---|---| | Airway | Voice, consciousness, secretions, seizure, vomiting | Reduced consciousness may threaten airway | Position, suction, airway support; early expert help if deteriorating | Encephalopathy/ICH may worsen rapidly | | Breathing | RR, SpO₂, work of breathing, crackles, frothy sputum | Pulmonary edema may be the target-organ injury | Oxygen only if hypoxemic; NIV when appropriate; prepare intubation if failing | Sudden fatigue, worsening edema | | Circulation | Repeat BP correctly, HR/rhythm, perfusion, pulses in all limbs | Pulse deficit or abrupt pain suggests aortic syndrome | Monitor, IV access, ECG; immediate anti-impulse therapy if dissection suspected | Rupture, shock, ischemia | | Disability | GCS/mental status, focal deficits, seizure, headache, vision | Encephalopathy, ICH, AIS, PRES | Glucose, urgent neuroimaging as indicated; follow stroke-specific BP targets | Herniation, seizure | | Exposure | Pregnancy status, edema, rash, stimulant clues, medication patches | Secondary cause or pregnancy syndrome may be apparent | Pregnancy testing when relevant; remove/stop causative drug | Eclampsia, toxidrome | ### Confirm the blood pressure Before committing to a diagnosis, unless the patient is crashing: - use an appropriately sized cuff; - repeat the measurement after a brief interval; - measure both arms when acute aortic syndrome is plausible; - consider manual confirmation when the automated reading is implausible, rhythm is irregular, or cuff fit is poor; - identify severe pain, agitation, hypoxemia, urinary retention, withdrawal, or medication omission that can transiently elevate BP. A markedly abnormal BP remains clinically important even when a reversible contributor exists, but measurement error is common and can lead to iatrogenic hypotension. --- ## 5. Identify acute target-organ damage ### Neurologic Look for: - confusion, agitation, drowsiness; - seizures; - visual disturbance; - severe headache with neurologic change; - focal weakness, aphasia, neglect, ataxia; - papilledema or retinal hemorrhage/exudate; - nausea/vomiting with altered cognition. #### Hypertensive encephalopathy / PRES The key syndrome is **diffuse cerebral dysfunction from failed autoregulation**, often with headache, confusion, visual symptoms, seizure, and sometimes MRI findings compatible with vasogenic edema. Diagnosis requires exclusion of stroke, hemorrhage, metabolic causes, infection, intoxication, and seizure-related states. ### Cardiovascular Evaluate for: - chest pain or pressure; - acute dyspnea/orthopnea; - pulmonary crackles, hypoxemia, pink frothy sputum; - new ischemic ECG changes; - elevated cardiac biomarkers in the correct context; - pulse asymmetry, neurologic deficits, new aortic regurgitation, or tearing chest/back pain suggesting acute aortic syndrome. ### Renal and hematologic Check for: - rising creatinine; - oliguria; - hematuria/proteinuria; - thrombocytopenia; - schistocytes; - elevated LDH with low haptoglobin suggesting microangiopathic hemolysis. Severe hypertension can both cause and result from kidney injury. Thrombotic microangiopathy from malignant hypertension may mimic thrombotic thrombocytopenic purpura; the broader clinical context and ADAMTS13 testing may be important when TTP remains possible. ### Ophthalmic Fundoscopy can identify: - flame hemorrhages; - cotton-wool spots; - hard exudates; - papilledema. Retinal findings support acute microvascular injury but absence of papilledema does not exclude a hypertensive emergency. --- ## 6. Diagnostic workup Testing should be driven by the suspected organ injury rather than by BP alone. ### Common initial studies - 12-lead ECG - serum creatinine, electrolytes, glucose - CBC with platelets - urinalysis ± urine protein assessment - high-sensitivity troponin when ACS or myocardial injury is suspected - pregnancy test when relevant - chest radiograph for pulmonary edema or thoracic symptoms - point-of-care ultrasound where expertise exists ### Add when indicated - noncontrast CT head for acute neurologic symptoms - CTA head/neck for suspected stroke or vascular pathology - CTA chest/abdomen/pelvis for suspected acute aortic syndrome - echocardiography for acute heart failure, structural disease, or aortic regurgitation - LDH, bilirubin, haptoglobin, reticulocytes, peripheral smear for suspected microangiopathic hemolysis - toxicology testing when it would change management - plasma/urine metanephrine testing **after stabilization** when pheochromocytoma remains plausible; do not delay crisis treatment for confirmatory testing. ★ **NEXT BEST STEP:** In suspected aortic dissection or stroke, imaging and organ-specific therapy should proceed in parallel with controlled BP treatment; do not spend an hour completing a routine hypertension workup first. --- ## 7. General treatment principles ### STANDARD OF CARE 1. **Treat in a monitored environment.** Hypertensive emergency generally warrants ICU or equivalent high-acuity monitoring.[1] 2. **Use titratable short-acting IV medication** for most true emergencies.[1] 3. **Choose the drug according to the organ syndrome.** 4. **Avoid excessive early reduction** unless a compelling condition requires it.[1] 5. **Reassess perfusion and organ function continuously.** 6. **Transition to oral therapy only after the acute syndrome is controlled and the trajectory is stable.** ### Generic BP goal when there is no compelling condition The 2025 AHA/ACC guideline recommends avoiding an initial SBP reduction greater than about **25% in the first hour**, followed by reduction to **<160/100–110 mm Hg over the next 2–6 hours**, then cautious normalization over the next 24–48 hours.[1] This is not the target for aortic dissection, acute stroke, intracerebral hemorrhage, or pregnancy-related severe hypertension. --- ## 8. Intravenous antihypertensive medications Doses below are adult guideline ranges and assume a monitored setting. Adjust for age, organ function, contraindications, and local protocols.[1,7] | Drug | Typical adult dosing | Useful clinical contexts | Major cautions / limitations | |---|---|---|---| | **Nicardipine** | Start **5 mg/h IV**; increase by **2.5 mg/h every 5 min** to max **15 mg/h** | Encephalopathy, many neurologic emergencies, general titratable BP control | Avoid/individualize in advanced aortic stenosis; reflex tachycardia possible | | **Clevidipine** | Start **1–2 mg/h IV**, rapidly titrate by doubling every ~90 s until near goal, then smaller increases; 2025 AHA/ACC table lists max **21 mg/h** | Very rapid titration; neurologic/cardiac settings | Lipid emulsion; avoid in relevant egg/soy-product allergy and major lipid-metabolism disorders; follow product/local maximums | | **Labetalol** | Intermittent IV bolus or infusion; common emergency regimens use **10–20 mg IV initially**, then repeated/titrated doses or infusion per protocol | Many emergencies; pregnancy; aortic syndrome when appropriate | Bradycardia, heart block, asthma/bronchospasm, decompensated systolic HF | | **Esmolol** | **0.5–1 mg/kg IV loading**, then **50–300 mcg/kg/min** infusion | Acute aortic syndrome; situations requiring rapidly reversible beta-blockade | Bradycardia, AV block, acute decompensated HF, bronchospasm risk | | **Nitroglycerin** | Start around **5 mcg/min IV**, titrate rapidly to clinical/BP response using local protocol | Acute pulmonary edema, ACS with hypertension | Headache, tachyphylaxis; profound hypotension with PDE-5 inhibitors; weak arterial effect at low doses | | **Sodium nitroprusside** | Start **0.3–0.5 mcg/kg/min IV**, titrate; use shortest duration possible | Selected refractory emergencies, after beta-blockade in some aortic cases | Cyanide/thiocyanate toxicity, overshoot hypotension; caution renal/hepatic dysfunction; invasive BP monitoring often appropriate | | **Hydralazine** | Common urgent regimen **5–10 mg IV**, repeat per protocol | Pregnancy-related severe hypertension when used in obstetric protocol | Response can be unpredictable and prolonged; not preferred for most nonpregnant emergencies | | **Phentolamine** | Common crisis dosing **2–5 mg IV**, repeated as needed under close monitoring | Pheochromocytoma/catecholamine excess | Tachycardia, hypotension; specialist guidance advised | #### Why nicardipine and clevidipine are often attractive They provide smooth, easily titratable arterial vasodilation. The 2025 guideline notes limited trials suggesting nicardipine may reach short-term BP targets more reliably than labetalol and clevidipine may lower pressure faster than nicardipine, but there is **no high-quality evidence that one IV agent improves mortality across all hypertensive emergencies**.[1] #### Why nitroprusside is no longer a universal default It is potent and rapidly titratable but carries risks of overshoot hypotension and cyanide/thiocyanate toxicity. More organ-specific agents are usually preferred when available.[1,7] --- ## 9. Syndrome-specific treatment ### 9.1 Acute aortic syndrome / aortic dissection This is one of the most time-critical BP emergencies. #### Goal The 2025 AHA/ACC guideline recommends **SBP ≤120 mm Hg within about 20 minutes**, provided organ perfusion is maintained.[1] #### Sequence matters 1. Start **beta-blockade first** to reduce heart rate and aortic wall impulse (commonly esmolol or labetalol). 2. If SBP remains above goal, add a titratable vasodilator such as nicardipine or nitroprusside. 3. Provide aggressive analgesia and immediate cardiothoracic/vascular surgical consultation. ⚠ **COMMON TRAP:** Starting a pure vasodilator before adequate beta-blockade may increase reflex tachycardia and shear stress. #### Practical targets - SBP: generally **≤120 mm Hg**, individualized to maintain perfusion[1] - HR: often targeted near **60 beats/min** in anti-impulse protocols[7] --- ### 9.2 Acute ischemic stroke Do **not** apply the generic 25%-reduction rule automatically. The 2026 AHA/ASA acute ischemic stroke guideline recommends:[5] - **Before IV thrombolysis:** lower BP to **<185/110 mm Hg**. - **After IV thrombolysis:** maintain **<180/105 mm Hg for at least 24 hours**. - **Before EVT when IV thrombolysis was not given:** maintaining **≤185/110 mm Hg** is reasonable. - **During and for 24 hours after EVT:** maintaining **≤180/105 mm Hg** is reasonable. - After successful thrombectomy, **intensive SBP lowering to <140 mm Hg is harmful and is not recommended** in the populations addressed by the guideline.[5] For patients not undergoing reperfusion, permissive hypertension is often appropriate unless BP is extremely high or another compelling emergency such as aortic dissection, acute coronary syndrome, or pulmonary edema requires treatment. Follow the current stroke protocol. --- ### 9.3 Spontaneous intracerebral hemorrhage For patients with **mild-to-moderate ICH** presenting with SBP **150–220 mm Hg**, the 2022 AHA/ASA guideline states that acute lowering to a target near **140 mm Hg**, maintaining approximately **130–150 mm Hg**, is safe and may be reasonable. Acute lowering to **<130 mm Hg** is potentially harmful.[4] Priorities: - smooth sustained control rather than oscillating BP; - rapid neuroimaging; - reversal of anticoagulation when indicated; - neurosurgical/neurocritical-care consultation; - management of intracranial pressure and other ICH priorities. --- ### 9.4 Hypertensive encephalopathy / PRES When diffuse neurologic dysfunction is attributed to severe hypertension after excluding hemorrhage, ischemic stroke, metabolic disease, infection, and toxic causes: - use a titratable IV agent such as nicardipine or labetalol; - generally reduce MAP/SBP cautiously, often using the default **no more than ~25% in the first hour** principle; - avoid rapid normalization; - treat seizures when present; - obtain MRI when PRES is suspected and the patient is stable enough. Clinical improvement in mental status with controlled BP reduction supports the diagnosis but is not a substitute for excluding other emergencies. --- ### 9.5 Acute cardiogenic pulmonary edema with severe hypertension The pathophysiology is often abrupt afterload excess with pulmonary vascular congestion; some patients are not markedly volume overloaded. #### Priorities - noninvasive positive-pressure ventilation when appropriate; - IV **nitroglycerin** when severe hypertension/afterload excess is prominent; - a titratable arterial vasodilator such as clevidipine in selected patients; - loop diuretic when true congestion/volume overload is present; - treat ACS, arrhythmia, renal failure, or valve disease when causative.[1] **Beta-blockers are not used to acutely lower BP in active pulmonary edema with decompensated heart failure.**[1] ⚠ **COMMON TRAP:** Giving repeated fluid boluses because the patient is tachycardic despite clear pulmonary edema. --- ### 9.6 Acute coronary syndrome with severe hypertension Goals are to reduce myocardial oxygen demand without compromising coronary perfusion. Options may include: - IV nitroglycerin for persistent ischemia/hypertension when not contraindicated; - beta-blockade in appropriately selected patients without acute heart failure, shock, bradycardia, or conduction disease; - nicardipine or other titratable agents when needed.[1] Avoid precipitous reductions in diastolic pressure, especially in patients with severe coronary disease who depend on diastolic coronary perfusion. --- ### 9.7 Acute kidney injury / malignant hypertension The patient may have: - rising creatinine; - hematuria/proteinuria; - retinal injury; - microangiopathic hemolytic anemia; - thrombocytopenia. Use controlled IV BP reduction and carefully monitor renal function, urine output, potassium, acid-base status, and hemolysis markers. Nicardipine or other titratable agents are commonly used; the choice should reflect the clinical context and local critical-care practice. A transient creatinine rise can occur during BP reduction because autoregulation is being reset. The aim is not to preserve the presenting pressure but to avoid excessive hypotension while preventing ongoing vascular injury. --- ### 9.8 Pheochromocytoma or catecholamine crisis Features can include episodic or sustained severe hypertension, tachycardia, diaphoresis, headache, hyperglycemia, lactic acidosis, cardiomyopathy, pulmonary edema, or shock. #### Principle **Alpha blockade/vasodilation must precede unopposed beta blockade** when catecholamine excess is suspected. IV phentolamine, nicardipine, or other expert-directed vasodilator therapy may be used.[1,7] ⚠ **RED FLAG:** Pure beta-blockade before adequate alpha control in pheochromocytoma can worsen vasoconstriction and hypertension. --- ### 9.9 Severe hypertension in pregnancy / postpartum Severe-range pregnancy hypertension is generally **SBP ≥160 mm Hg and/or DBP ≥110 mm Hg**. ACOG recommends urgent treatment, ideally within **30–60 minutes** of confirmed persistent severe hypertension, to reduce maternal stroke risk.[6] First-line urgent agents include: - **IV labetalol**; - **IV hydralazine**; - **immediate-release oral nifedipine**, especially when IV access is not yet available.[6] The 2025 AHA/ACC guideline reproduces commonly used urgent pregnancy regimens, including labetalol **10–20 mg IV initially**, hydralazine **5 mg IV/IM initially**, and nifedipine **10–20 mg orally**, with protocolized repeat dosing.[1] If preeclampsia with severe features/eclampsia is present, magnesium sulfate and obstetric decision-making regarding delivery are separate critical priorities. Do not manage pregnancy-related severe hypertension as a routine nonpregnant hypertensive emergency. --- ## 10. Severe asymptomatic hypertension: what not to do The 2024 AHA scientific statement and 2025 AHA/ACC guideline emphasize that inpatient or ED patients with severe BP elevation **without acute target-organ injury** should not routinely receive IV antihypertensive therapy solely to normalize a number.[1,2] ### Better approach 1. Recheck BP with correct technique. 2. Treat pain, anxiety, hypoxemia, urinary retention, withdrawal, or other reversible stressors. 3. Determine whether chronic antihypertensives were missed or held. 4. Assess for symptoms/signs of organ injury. 5. Restart or adjust an oral regimen when appropriate. 6. Arrange timely outpatient follow-up and evaluation for chronic hypertension/secondary causes. Observational studies cited by the AHA have associated unnecessary acute inpatient treatment with hypotension, AKI, and longer hospitalization.[2] ★ **HIGH YIELD:** Severe BP **without** acute organ injury is not a reason to “chase the number” with PRN IV medication. --- ## 11. Monitoring and reassessment ### Continuous or frequent monitoring - BP every few minutes during active titration - continuous ECG - pulse oximetry when respiratory compromise is possible - neurologic checks for brain syndromes - urine output in severe disease - serial creatinine/electrolytes - serial troponin/ECG when ACS is suspected - serial hemolysis studies when microangiopathy is present An arterial catheter is reasonable when very rapid titration is required, when noninvasive measurements are unreliable, or when the margin between adequate treatment and hypoperfusion is narrow. ### Reassessment questions after each dose/titration - Has the target pressure been reached too quickly? - Is mental status improving or worsening? - Is chest pain resolving? - Is oxygenation/work of breathing improving? - Is urine output preserved? - Are new neurologic deficits appearing? - Are limb perfusion or pulses changing? - Is the patient becoming dizzy, oliguric, bradycardic, or hypotensive? --- ## 12. Anticipation of deterioration | Scenario | Warning signs | What to prepare for | |---|---|---| | Aortic dissection | new hypotension, pulse loss, neurologic deficit, pericardial effusion, severe aortic regurgitation | immediate surgery/transfer, blood products, airway/critical care | | ICH/PRES | falling GCS, recurrent seizure, anisocoria | airway control, repeat CT, neurocritical care, ICP management | | Pulmonary edema | rising work of breathing, refractory hypoxemia, fatigue | NIV escalation, intubation, vasodilator intensification | | ACS | ventricular arrhythmia, shock, ongoing ischemia | cath-lab pathway, defibrillation capability, mechanical support evaluation | | Malignant hypertension/TMA | worsening AKI, hemolysis, thrombocytopenia | nephrology/hematology input, dialysis preparation, exclude TTP | | Pregnancy | seizure, pulmonary edema, fetal compromise, HELLP features | magnesium, obstetric emergency response, delivery planning | | Catecholamine crisis | hyperthermia, cardiomyopathy, arrhythmia, shock | ICU, alpha-directed therapy, mechanical support if needed | --- ## 13. Transition to oral therapy Once the emergency is controlled: - identify the chronic BP regimen and adherence barriers; - investigate secondary hypertension when clinically indicated; - transition from IV to oral agents with sufficient overlap to prevent rebound; - simplify the regimen when possible; - address substance use or medication triggers; - arrange kidney, cardiology, neurology, obstetric, vascular, or endocrine follow-up as appropriate; - establish a home BP plan with validated cuff and clear thresholds for seeking care. Avoid discharging a patient after a true hypertensive emergency without a plan for the organ injury itself; BP control is only one component of definitive care. --- ## 14. Secondary hypertension clues after stabilization Consider targeted workup for: - primary aldosteronism; - renal parenchymal disease; - renal artery stenosis/fibromuscular dysplasia; - pheochromocytoma/paraganglioma; - Cushing syndrome; - thyroid disease; - obstructive sleep apnea; - coarctation; - drug/substance causes. The 2025 AHA/ACC guideline expanded emphasis on detection of secondary causes, including broader screening for primary aldosteronism in resistant hypertension.[1] --- ## 15. Common pitfalls | Pitfall | Why it is dangerous | Better approach | |---|---|---| | Defining emergency by BP alone | Leads to unnecessary IV therapy | Require acute target-organ injury | | Rapidly normalizing chronic severe hypertension | Cerebral, coronary, renal hypoperfusion | Controlled syndrome-specific reduction | | Using generic 25% rule in aortic dissection | Too slow for a time-critical aortic catastrophe | Anti-impulse therapy; SBP ≤120 rapidly if tolerated | | Lowering BP aggressively in ischemic stroke without indication | Can reduce penumbral perfusion | Follow 2026 stroke-specific thresholds | | Treating post-thrombectomy BP to <140 routinely | 2026 AHA/ASA guideline identifies harm | Use current EVT target protocol | | Pure beta-blockade in pheochromocytoma | Unopposed alpha vasoconstriction | Alpha blockade/vasodilation first | | Beta-blocker for active hypertensive pulmonary edema | May worsen decompensated HF | Vasodilator + ventilatory support; treat congestion/cause | | PRN IV hydralazine for asymptomatic inpatient BP | Unpredictable fall and no proven benefit | Correct drivers and use scheduled oral therapy when indicated | | Ignoring pregnancy-specific protocols | Maternal stroke/eclampsia risk | Treat persistent ≥160/110 promptly with obstetric pathway | | Forgetting medication withdrawal | Rebound hypertension persists | Identify clonidine/other withdrawal and treat appropriately | --- ## 16. Diagnostic and management algorithm ```text Severely elevated BP ↓ Repeat correctly + rapid ABCDE assessment ↓ Evidence of NEW/WORSENING acute target-organ damage? ├─ NO │ ↓ │ Severe asymptomatic hypertension │ - Treat pain/anxiety/hypoxemia/retention/withdrawal │ - Restart/intensify oral therapy when appropriate │ - Avoid reflex IV treatment │ - Arrange follow-up │ └─ YES ↓ Hypertensive emergency ↓ Identify dominant syndrome ├─ Aortic dissection → beta-block first → SBP ≤120 rapidly ├─ AIS → follow 2026 stroke BP thresholds ├─ ICH → smooth target ~140; maintain 130–150 if eligible ├─ Pulmonary edema → NIV + nitrate/vasodilator strategy ├─ ACS → anti-ischemic + titratable BP control ├─ Encephalopathy/PRES → controlled IV reduction ├─ Pregnancy → urgent obstetric protocol ├─ Catecholamine crisis → alpha-directed therapy └─ Other emergency → default ≤25% first-hour reduction ↓ Continuous reassessment of perfusion and organ function ↓ Definitive cause-specific treatment + transition to oral regimen ``` --- ## 17. Acute management checklist ### Recognition - [ ] Repeat BP with appropriate cuff/technique - [ ] Identify acute neurologic, cardiac, pulmonary, renal, retinal, aortic, pregnancy, or microangiopathic injury - [ ] Check medication adherence and recent drug/substance exposure ### Stabilization - [ ] Cardiac monitor and IV access - [ ] Oxygen only if hypoxemic; ventilatory support if needed - [ ] Obtain ECG and targeted labs - [ ] Obtain urgent imaging for neurologic or aortic syndrome - [ ] Choose **syndrome-specific** BP target - [ ] Use titratable IV agent for true emergency ### Reassessment - [ ] Confirm rate of BP decline is not excessive - [ ] Recheck neurologic status - [ ] Reassess chest pain and respiratory status - [ ] Track creatinine and urine output - [ ] Repeat organ-specific studies when clinically indicated ### Disposition - [ ] ICU/high-acuity care for true hypertensive emergency - [ ] Definitive specialty management of the injured organ - [ ] Transition to durable oral regimen - [ ] Evaluate secondary cause/adherence after stabilization --- ## 18. Guideline differences and jurisdiction notes ### United States: 2025 AHA/ACC The 2025 guideline provides a practical definition of hypertensive emergency, ICU disposition, the default staged reduction strategy, IV drug tables, and explicit disease-specific exceptions.[1] ### Europe: 2024 ESC The 2024 ESC guideline updates the broader framework for hypertension and reinforces individualized management of severe hypertension and acute organ injury. European practice also draws on the ESC Council position document on hypertensive emergencies, which emphasizes that the **type of organ injury determines the drug, target, and timeframe**.[3,7] ### Acute-care AHA statement The 2024 AHA scientific statement is especially important for avoiding **overtreatment of asymptomatic inpatient BP elevation**. It highlights the weak evidence base for treating a transient inpatient BP number in the absence of acute organ injury and the potential for harm.[2] ### Stroke The 2026 AHA/ASA ischemic stroke guideline supersedes older US acute-ischemic-stroke guidance and specifically warns against overly intensive BP lowering after thrombectomy.[5] --- ## 19. Standard of care vs emerging evidence ### STANDARD OF CARE - Diagnose hypertensive emergency by **acute target-organ injury**, not BP alone.[1–3] - ICU/high-acuity monitoring and IV titratable therapy for most true emergencies.[1] - Syndrome-specific targets for aorta, stroke, ICH, pregnancy, pulmonary edema, and ACS.[1,4–6] - Avoid rapid IV treatment of severe asymptomatic inpatient hypertension.[1,2] ### EMERGING EVIDENCE - Optimal BP targets after endovascular thrombectomy continue to evolve; recent randomized evidence has shifted practice away from intensive post-EVT lowering, reflected in the 2026 AHA/ASA guideline.[5] - Comparative effectiveness of nicardipine, clevidipine, and labetalol for hard clinical outcomes remains uncertain; existing trials mainly examine speed/precision of target achievement rather than mortality.[1] - Better phenotyping of malignant hypertension, hypertensive microangiopathy, and secondary causes may improve individualized therapy. ### EXPERIMENTAL / INVESTIGATIONAL - Novel biomarkers or automated closed-loop BP titration systems are not yet standard care. - Device-based chronic hypertension therapies such as renal denervation have no role in the initial stabilization of a hypertensive emergency. --- ## 20. Exam-focused review ### Foundation / USMLE Step 1 Know the physiology: - chronic hypertension shifts autoregulation to higher pressures; - abrupt normalization can cause ischemia; - hypertensive encephalopathy is a failure of cerebral autoregulation with vasogenic edema; - aortic dissection requires reduction of both BP and shear/impulse. ### USMLE Step 2 CK Priority questions usually test: - **organ injury present?** - **which syndrome determines the BP target?** - **IV or oral therapy?** - **what should happen before vasodilation in dissection?** ### Step 3 / Resident Be able to choose an agent and monitor complications: - nicardipine/clevidipine for smooth titration; - esmolol/labetalol for aortic impulse control; - nitroglycerin for hypertensive pulmonary edema/ACS; - pregnancy-specific labetalol/hydralazine/nifedipine pathway; - avoid unnecessary IV treatment in asymptomatic severe BP. ### MRCP / ABIM / Boards Expect nuanced questions involving: - malignant hypertension with AKI/TMA; - stroke-specific thresholds; - aortic dissection sequence; - catecholamine crisis and unopposed alpha effect; - acute pulmonary edema and why beta-blockade is inappropriate during active decompensation; - the distinction between chronic severe hypertension and acute end-organ injury. --- ## 21. Original board-style MCQs ### Question 1 A 64-year-old man has BP 228/132 mm Hg, acute tearing chest pain radiating to the back, and a new pulse deficit. He is alert and oxygenating well. Which initial pharmacologic strategy is best? A. IV nitroprusside before any rate control B. IV esmolol followed by titratable vasodilator if needed C. Oral amlodipine and observation D. IV hydralazine bolus only E. Sublingual nifedipine **Answer: B.** Suspected acute aortic syndrome requires rapid anti-impulse therapy. Beta-blockade should precede a pure vasodilator to prevent reflex tachycardia and increased shear. The target SBP is generally ≤120 mm Hg rapidly if perfusion is maintained.[1] --- ### Question 2 A hospitalized patient with pneumonia has repeated BP readings around 192/106 mm Hg but no chest pain, neurologic deficit, pulmonary edema, AKI, retinal findings, or other acute target-organ damage. Which approach best reflects current guidance? A. PRN IV hydralazine whenever SBP exceeds 180 B. IV nicardipine infusion to normalize BP within 2 hours C. Reassess measurement and reversible stressors, then use scheduled oral therapy if indicated D. Nitroprusside infusion E. Emergent dialysis **Answer: C.** Severe asymptomatic inpatient BP elevation should not routinely be treated with IV medication solely to lower the number. Treat reversible contributors and manage chronic hypertension deliberately.[1,2] --- ### Question 3 A patient with acute ischemic stroke is otherwise eligible for IV thrombolysis. BP is 198/118 mm Hg. What is the relevant pre-thrombolysis BP goal? A. <220/120 mm Hg B. <200/110 mm Hg C. <185/110 mm Hg D. <160/90 mm Hg E. <140/80 mm Hg **Answer: C.** The 2026 AHA/ASA guideline recommends reducing BP to <185/110 mm Hg before IV thrombolysis.[5] --- ### Question 4 A 58-year-old woman with mild-to-moderate spontaneous ICH presents with SBP 188 mm Hg. Which acute target is most consistent with AHA/ASA guidance? A. SBP <100 mm Hg immediately B. SBP <120 mm Hg immediately C. Target ~140 mm Hg and maintain approximately 130–150 mm Hg D. No BP treatment until 24 hours E. Target <130 mm Hg **Answer: C.** In eligible mild-to-moderate ICH with presenting SBP 150–220 mm Hg, smooth reduction toward 140 with maintenance 130–150 is safe and may be reasonable; <130 may be harmful.[4] --- ### Question 5 A patient with severe hypertension, diaphoresis, tachycardia, and known pheochromocytoma develops a crisis. Which principle is essential? A. Pure beta-blockade should precede all other therapy B. Alpha-directed vasodilation should precede unopposed beta-blockade C. BP should never be lowered acutely D. Oral thiazide is first-line emergency treatment E. Nitroglycerin is contraindicated in all catecholamine crises **Answer: B.** Unopposed beta-blockade can worsen alpha-mediated vasoconstriction. Alpha blockade/vasodilation should be established first.[1,7] --- ## 22. Key takeaways 1. **Hypertensive emergency = severe BP + acute target-organ damage.** 2. **A number alone is not an emergency.** 3. For most emergencies without a compelling condition, reduce BP cautiously: no more than ~25% in the first hour, then toward <160/100–110 over 2–6 hours.[1] 4. **Aortic dissection is different:** beta-block first; SBP ≤120 rapidly if tolerated.[1] 5. **Stroke is different:** follow 2026 AHA/ASA reperfusion-specific targets.[5] 6. **ICH is different:** smooth reduction toward ~140 with avoidance of <130 in eligible patients.[4] 7. **Pregnancy is different:** persistent severe-range BP requires urgent obstetric antihypertensive therapy.[6] 8. Do not reflexively treat severe asymptomatic inpatient BP with IV medication.[1,2] 9. Drug choice is determined by the injured organ and comorbidities. 10. Reassessment is continuous; overshoot hypotension can be as dangerous as undertreatment. --- ## References 1. Jones DW, Ferdinand KC, Taler SJ, et al. **2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.** *Circulation.* 2025. DOI: **10.1161/CIR.0000000000001356**. Parallel publication: *Hypertension.* 2025;82:e212-e316. DOI: **10.1161/HYP.0000000000000249**. JACC version DOI: **10.1016/j.jacc.2025.05.007**. 2. Bress AP, Anderson TS, Flack JM, et al. **The Management of Elevated Blood Pressure in the Acute Care Setting: A Scientific Statement From the American Heart Association.** *Hypertension.* 2024;81:e94-e106. DOI: **10.1161/HYP.0000000000000238**. 3. McEvoy JW, McCarthy CP, Bruno RM, et al. **2024 ESC Guidelines for the management of elevated blood pressure and hypertension.** *Eur Heart J.* 2024;45:3912-4018. DOI: **10.1093/eurheartj/ehae178**. PMID: **39210715**. 4. Greenberg SM, Ziai WC, Cordonnier C, et al. **2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage.** *Stroke.* 2022;53:e282-e361. DOI: **10.1161/STR.0000000000000407**. 5. American Heart Association/American Stroke Association. **2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke.** *Stroke.* 2026;57:e316-e436. DOI: **10.1161/STR.0000000000000513**. 6. American College of Obstetricians and Gynecologists. **ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.** *Obstet Gynecol.* 2019;133:e174-e180. DOI: **10.1097/AOG.0000000000003075**. PMID: **30575639**. 7. van den Born BJH, Lip GYH, Brguljan-Hitij J, et al. **ESC Council on hypertension position document on the management of hypertensive emergencies.** *Eur Heart J Cardiovasc Pharmacother.* 2019;5:37-46. DOI: **10.1093/ehjcvp/pvy032**. PMID: **30165588**. Corrigendum DOI: **10.1093/ehjcvp/pvy040**. 8. American Heart Association. **2025 High Blood Pressure Guideline — Professional Heart Daily.** Updated August 14, 2025. Official guideline hub: https://professional.heart.org/en/science-news/2025-high-blood-pressure-guideline 9. European Society of Cardiology. **2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension.** Official guideline hub: https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/elevated-blood-pressure-and-hypertension/ --- **Evidence note:** The strongest contemporary sources for this article are the 2025 AHA/ACC adult blood-pressure guideline, the 2024 AHA acute-care scientific statement, the 2024 ESC hypertension guideline, the 2026 AHA/ASA ischemic-stroke guideline, and the 2022 AHA/ASA ICH guideline. Drug doses and targets must always be reconciled with local formularies, product labeling, organ-specific protocols, and the patient's physiology.7:["$","$L17",null,{"article":{"id":"medical-0020","title":"Hypertensive Emergency","slug":"hypertensive-emergency","description":"A hypertensive emergency is severe blood-pressure elevation accompanied by new or worsening acute target-organ damage. The number on the sphygmomanometer alone does not define the emergency. Acute encephalopathy, intr…","aliases":[],"category":"Cardiology","tags":["Cardiology","Emergency Medicine","Critical Care","Vascular Medicine"],"updatedAt":"2026-09-09","body":"$18","headings":[{"id":"one-minute-summary","text":"One-minute summary","level":2},{"id":"1-definitions-and-terminology","text":"1. Definitions and terminology","level":2},{"id":"severe-hypertension","text":"Severe hypertension","level":3},{"id":"hypertensive-emergency","text":"Hypertensive emergency","level":3},{"id":"severe-asymptomatic-hypertension","text":"Severe asymptomatic hypertension","level":3},{"id":"2-pathophysiology","text":"2. Pathophysiology","level":2},{"id":"autoregulation-explains-why-overshoot-is-dangerous","text":"Autoregulation explains why overshoot is dangerous","level":3},{"id":"3-causes-and-precipitants","text":"3. Causes and precipitants","level":2},{"id":"4-first-5-minutes-confirm-the-syndrome","text":"4. First 5 minutes: confirm the syndrome","level":2},{"id":"immediate-priorities","text":"Immediate priorities","level":3},{"id":"confirm-the-blood-pressure","text":"Confirm the blood pressure","level":3},{"id":"5-identify-acute-target-organ-damage","text":"5. Identify acute target-organ damage","level":2},{"id":"neurologic","text":"Neurologic","level":3},{"id":"cardiovascular","text":"Cardiovascular","level":3},{"id":"renal-and-hematologic","text":"Renal and hematologic","level":3},{"id":"ophthalmic","text":"Ophthalmic","level":3},{"id":"6-diagnostic-workup","text":"6. Diagnostic workup","level":2},{"id":"common-initial-studies","text":"Common initial studies","level":3},{"id":"add-when-indicated","text":"Add when indicated","level":3},{"id":"7-general-treatment-principles","text":"7. General treatment principles","level":2},{"id":"standard-of-care","text":"STANDARD OF CARE","level":3},{"id":"generic-bp-goal-when-there-is-no-compelling-condition","text":"Generic BP goal when there is no compelling condition","level":3},{"id":"8-intravenous-antihypertensive-medications","text":"8. Intravenous antihypertensive medications","level":2},{"id":"9-syndrome-specific-treatment","text":"9. Syndrome-specific treatment","level":2},{"id":"91-acute-aortic-syndrome-aortic-dissection","text":"9.1 Acute aortic syndrome / aortic dissection","level":3},{"id":"92-acute-ischemic-stroke","text":"9.2 Acute ischemic stroke","level":3},{"id":"93-spontaneous-intracerebral-hemorrhage","text":"9.3 Spontaneous intracerebral hemorrhage","level":3},{"id":"94-hypertensive-encephalopathy-pres","text":"9.4 Hypertensive encephalopathy / PRES","level":3},{"id":"95-acute-cardiogenic-pulmonary-edema-with-severe-hypertension","text":"9.5 Acute cardiogenic pulmonary edema with severe hypertension","level":3},{"id":"96-acute-coronary-syndrome-with-severe-hypertension","text":"9.6 Acute coronary syndrome with severe hypertension","level":3},{"id":"97-acute-kidney-injury-malignant-hypertension","text":"9.7 Acute kidney injury / malignant hypertension","level":3},{"id":"98-pheochromocytoma-or-catecholamine-crisis","text":"9.8 Pheochromocytoma or catecholamine crisis","level":3},{"id":"99-severe-hypertension-in-pregnancy-postpartum","text":"9.9 Severe hypertension in pregnancy / postpartum","level":3},{"id":"10-severe-asymptomatic-hypertension-what-not-to-do","text":"10. Severe asymptomatic hypertension: what not to do","level":2},{"id":"better-approach","text":"Better approach","level":3},{"id":"11-monitoring-and-reassessment","text":"11. Monitoring and reassessment","level":2},{"id":"continuous-or-frequent-monitoring","text":"Continuous or frequent monitoring","level":3},{"id":"reassessment-questions-after-each-dosetitration","text":"Reassessment questions after each dose/titration","level":3},{"id":"12-anticipation-of-deterioration","text":"12. Anticipation of deterioration","level":2},{"id":"13-transition-to-oral-therapy","text":"13. Transition to oral therapy","level":2},{"id":"14-secondary-hypertension-clues-after-stabilization","text":"14. Secondary hypertension clues after stabilization","level":2},{"id":"15-common-pitfalls","text":"15. Common pitfalls","level":2},{"id":"16-diagnostic-and-management-algorithm","text":"16. Diagnostic and management algorithm","level":2},{"id":"17-acute-management-checklist","text":"17. Acute management checklist","level":2},{"id":"recognition","text":"Recognition","level":3},{"id":"stabilization","text":"Stabilization","level":3},{"id":"reassessment","text":"Reassessment","level":3},{"id":"disposition","text":"Disposition","level":3},{"id":"18-guideline-differences-and-jurisdiction-notes","text":"18. Guideline differences and jurisdiction notes","level":2},{"id":"united-states-2025-ahaacc","text":"United States: 2025 AHA/ACC","level":3},{"id":"europe-2024-esc","text":"Europe: 2024 ESC","level":3},{"id":"acute-care-aha-statement","text":"Acute-care AHA statement","level":3},{"id":"stroke","text":"Stroke","level":3},{"id":"19-standard-of-care-vs-emerging-evidence","text":"19. Standard of care vs emerging evidence","level":2},{"id":"standard-of-care","text":"STANDARD OF CARE","level":3},{"id":"emerging-evidence","text":"EMERGING EVIDENCE","level":3},{"id":"experimental-investigational","text":"EXPERIMENTAL / INVESTIGATIONAL","level":3},{"id":"20-exam-focused-review","text":"20. Exam-focused review","level":2},{"id":"foundation-usmle-step-1","text":"Foundation / USMLE Step 1","level":3},{"id":"usmle-step-2-ck","text":"USMLE Step 2 CK","level":3},{"id":"step-3-resident","text":"Step 3 / Resident","level":3},{"id":"mrcp-abim-boards","text":"MRCP / ABIM / Boards","level":3},{"id":"21-original-board-style-mcqs","text":"21. Original board-style MCQs","level":2},{"id":"question-1","text":"Question 1","level":3},{"id":"question-2","text":"Question 2","level":3},{"id":"question-3","text":"Question 3","level":3},{"id":"question-4","text":"Question 4","level":3},{"id":"question-5","text":"Question 5","level":3},{"id":"22-key-takeaways","text":"22. Key takeaways","level":2},{"id":"references","text":"References","level":2}],"readingMinutes":25},"linkedMarkdown":"$19","backlinks":[],"related":[],"previewBySlug":{"abcde-approach":{"title":"ABCDE Approach","description":"The ABCDE approach is a structured method for the immediate assessment and treatment of a deteriorating or critically ill patient: Airway, Breathing, Circulation, Disability, Exposure. The central rule is treat life-t…","category":"Emergency Medicine"},"acute-asthma-exacerbation":{"title":"Acute Asthma Exacerbation","description":"An asthma exacerbation is an acute or subacute worsening of dyspnea, wheeze, cough or chest tightness with a fall in expiratory airflow compared with the patient’s usual state. The attack is caused by variable airflow…","category":"Pulmonology"},"bacterial-meningitis":{"title":"Acute Bacterial Meningitis","description":"Acute bacterial meningitis is infection-driven inflammation of the leptomeninges and cerebrospinal fluid (CSF). It can progress over hours to sepsis, shock, cerebral edema, seizures, raised intracranial pressure, hern…","category":"Infectious Disease"},"acute-coronary-syndrome":{"title":"Acute Coronary Syndrome","description":"Acute coronary syndrome (ACS) is the clinical spectrum caused most often by acute coronary atherothrombosis after plaque rupture or erosion and includes ST-elevation myocardial infarction (STEMI), non-ST-elevation myo…","category":"Cardiology"},"acute-ischemic-stroke":{"title":"Acute Ischemic Stroke","description":"Acute ischemic stroke (AIS) is sudden neurological dysfunction caused by focal cerebral, retinal, or spinal cord ischemia, most often from arterial occlusion. The practical emergency question is not simply “is this a…","category":"Neurology"},"acute-kidney-injury":{"title":"Acute Kidney Injury","description":"Acute kidney injury (AKI) is an abrupt decline in kidney function identified by a rise in serum creatinine and/or reduced urine output. The current established international definition remains the KDIGO 2012 definitio…","category":"Nephrology"},"acute-pulmonary-embolism":{"title":"Acute Pulmonary Embolism","description":"Acute pulmonary embolism (PE) is obstruction of the pulmonary arterial circulation by thrombus, usually arising from deep veins of the legs or pelvis. The immediate threat is acute right-ventricular (RV) pressure over…","category":"Pulmonology"},"atrial-fibrillation":{"title":"Atrial Fibrillation","description":"Atrial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by chaotic atrial electrical activation and ineffective atrial contraction. On ECG it produces irregularly irregular RR intervals (when AV c…","category":"Cardiology"},"diabetic-ketoacidosis":{"title":"Diabetic Ketoacidosis","description":"Diabetic ketoacidosis (DKA) is an acute metabolic emergency caused by insufficient effective insulin activity together with excess counterregulatory hormones, producing ketogenesis, metabolic acidosis, osmotic diuresi…","category":"Endocrinology"},"dyslipidemia-in-adults":{"title":"Dyslipidemia in Adults","description":"Dyslipidemia is an abnormal concentration or composition of circulating lipoproteins that increases atherosclerotic cardiovascular disease (ASCVD) risk or, when triglycerides are very high, pancreatitis risk. LDL-cont…","category":"Cardiology"},"sepsis-and-septic-shock":{"title":"Sepsis and Septic Shock","description":"Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. Operationally, Sepsis-3 identifies organ dysfunction as an acute increase in SOFA score ≥2 points attributable to infec…","category":"Critical Care"},"upper-gastrointestinal-bleeding":{"title":"Upper Gastrointestinal Bleeding","description":"Upper gastrointestinal bleeding (UGIB) is bleeding arising proximal to the ligament of Treitz. It most commonly presents with hematemesis, coffee-ground emesis, melena, or—when brisk—hematochezia with hemodynamic inst…","category":"Gastroenterology"}},"categories":["Cardiology","Critical Care","Emergency Medicine","Endocrinology","Gastroenterology","Infectious Disease","Nephrology","Neurology","Pulmonology"]}]